<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694523</url>
  </required_header>
  <id_info>
    <org_study_id>M16-010</org_study_id>
    <secondary_id>2015-003623-65</secondary_id>
    <secondary_id>1311.30</secondary_id>
    <nct_id>NCT02694523</nct_id>
  </id_info>
  <brief_title>BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blind, double dummy, active comparator controlled, parallel
      design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066
      (risankizumab) compared to adalimumab to support registration for the treatment of moderate
      to severe chronic plaque psoriasis in adult patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of 2 parts (Part A and Part B).

      Part A:

        -  Participants were randomized to receive either risankizumab or adalimumab.

      Part B:

        -  Participants who received risankizumab in Part A continued to receive risankizumab in
           Part B

        -  Adalimumab nonresponders (&lt;PASI 50 at Week 16) switched to risankizumab in Part B;

        -  Adalimumab responders (PASI 90 at Week 16) continued to received adalimumab in Part B;

        -  Adalimumab inadequate responders (PASI 50 to &lt;PASI 90) were rerandomized to receive
           either risankizumab or adalimumab in Part B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Nonresponder imputation (NRI) was used for missing data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)</measure>
    <time_frame>Week 44</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI75 at Week 16 (Part A)</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI100 at Week 16 (Part A)</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)</measure>
    <time_frame>Week 44</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)</measure>
    <time_frame>Week 44</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)</measure>
    <time_frame>Week 44</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">684</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Adalimumab (Part A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab</intervention_name>
    <description>Risankizumab administered by subcutaneous (SC) injection</description>
    <arm_group_label>Risankizumab (Part A)</arm_group_label>
    <other_name>BI 655066</other_name>
    <other_name>ABBV-066</other_name>
    <other_name>SKYRIZI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection</description>
    <arm_group_label>Adalimumab (Part A)</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>ABT-D2E7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for risankizumab</intervention_name>
    <description>Placebo risankizumab administered by subcutaneous (SC) injection</description>
    <arm_group_label>Adalimumab (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo for adalimumab</intervention_name>
    <description>Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection</description>
    <arm_group_label>Risankizumab (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients. Women of childbearing potential* must be ready and able to
             use highly effective methods of birth control per ICH M3(R2) that result in a low
             failure rate of less than 1% per year when used consistently and correctly. A list of
             contraception methods meeting these criteria is provided in the patient information.

             *Women of childbearing potential are defined as:

               -  having experienced menarche and

               -  not postmenopausal (12 months with no menses without an alternative medical
                  cause) and

               -  not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy).

          -  Age ≥ 18 years at screening

          -  Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for
             at least 6 months before the first administration of study drug. Duration of diagnosis
             may be reported by the patient.

          -  Have stable moderate to severe chronic plaque psoriasis with or without psoriatic
             arthritis at both Screening and Baseline (Randomization):

               -  Have an involved body surface area (BSA) ≥ 10% and

               -  Have a Psoriasis Area and Severity Index (PASI) score ≥ 12 and

               -  Have a static Physician Global Assessment (sPGA) score of ≥ 3.

          -  Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as
             assessed by the investigator

          -  Must be candidates for treatment with adalimumab (Humira®) according to local label as
             confirmed by the investigator.

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          -  Patients with

               -  non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)

               -  current drug-induced psoriasis (including an exacerbation of psoriasis from beta
                  blockers, calcium channel blockers, or lithium)

               -  active ongoing inflammatory diseases other than psoriasis that might confound
                  trial evaluations according to investigator's judgment

          -  Previous exposure to ABBV-066

          -  Previous exposure to adalimumab (Humira®)

          -  Currently enrolled in another investigational study or less than 30 days or more from
             screening since completing another investigational drug or device study.

          -  Use of any restricted medication or any drug considered likely to interfere with the
             safe conduct of the study.

          -  Major surgery performed within 12 weeks prior to randomization or planned within 12
             months after screening (e.g. hip replacement, removal aneurysm, stomach ligation).

          -  Known chronic or relevant acute infections, such as active tuberculosis (TB), human
             immunodeficiency virus (HIV) or viral hepatitis; QuantiFERON® TB test or purified
             protein derivative (PPD) skin test will be performed according to local labelling for
             Humira®. If the result is positive, patients may participate in the study if further
             work up (according to local practice/guidelines) establishes conclusively that the
             patient has no evidence of active TB. If presence of latent TB is established, then
             treatment should have been initiated and maintained according to local country
             guidelines.

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell or squamous cell carcinoma
             of the skin or in situ carcinoma of uterine cervix.

          -  Evidence of a current or previous disease, medical condition (including chronic
             alcohol or drug abuse) other than psoriasis, surgical procedure (i.e., organ
             transplant), medical examination finding (including vital signs and electrocardiogram
             [ECG]), or laboratory value at the Screening Visit outside the reference range that in
             the opinion of the investigator is clinically significant and would make the study
             participant unreliable to adhere to the protocol or to complete the trial, compromise
             the safety of the patient, or compromise the quality of the data.

          -  History of allergy/hypersensitivity to a systemically administered biologic agent or
             its excipients

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Previous enrolment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <results_first_submitted>May 3, 2019</results_first_submitted>
  <results_first_submitted_qc>May 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2019</results_first_posted>
  <disposition_first_submitted>January 9, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 9, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 12, 2018</disposition_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Skin Diseases, Papulosquamous</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>ABBV-066</keyword>
  <keyword>BI 655066</keyword>
  <keyword>Risankizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02694523/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02694523/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 684 subjects were enrolled; 79 subjects failed screening and are excluded from the analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab (Part A)</title>
          <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
        </group>
        <group group_id="P2">
          <title>Risankizumab (Part A)</title>
          <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
        </group>
        <group group_id="P3">
          <title>Risankizumab/Risankizumab (Part B)</title>
          <description>Participants randomized to receive double-blind (DB) risankizumab in Part A continued to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, and 28 (Part B).</description>
        </group>
        <group group_id="P4">
          <title>Adalimumab/Adalimumab (Part B)</title>
          <description>Participants who were responders after receiving adalimumab in Part A continued to receive adalimumab 40 mg by subcutaneous (SC) injection every other week through Week 41 (Part B).</description>
        </group>
        <group group_id="P5">
          <title>Adalimumab/Risankizumab (Part B)</title>
          <description>Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
        </group>
        <group group_id="P6">
          <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
          <description>Participants who were inadequate responders after receiving adalimumab in Part A and rerandomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
        </group>
        <group group_id="P7">
          <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
          <description>Participants who were inadequate responders after receiving adalimumab in Part A and rerandomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="301"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="294"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="294">Participants who received risankizumab in Part A continued to received risankizumab in Part B</participants>
                <participants group_id="P4" count="144">Adalimumab responders in Part A continued to received adalimumab in Part B</participants>
                <participants group_id="P5" count="38">Adalimumab nonresponders in Part A switched to risankizumab in Part B</participants>
                <participants group_id="P6" count="56">Adalimumab inadequate responders in Part A, rerandomized to adalimumab in Part B</participants>
                <participants group_id="P7" count="53">Adalimumab inadequate responders in Part A, rerandomized to risankizumab in Part B</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="274"/>
                <participants group_id="P4" count="140"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab (Part A)</title>
          <description>Participants randomized to receive double blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Weeks 0, 1, and every other week for 15 weeks (Part A).</description>
        </group>
        <group group_id="B2">
          <title>Risankizumab (Part A)</title>
          <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4 (Part A).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="304"/>
            <count group_id="B2" value="301"/>
            <count group_id="B3" value="605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="13.09"/>
                    <measurement group_id="B2" value="45.3" spread="13.79"/>
                    <measurement group_id="B3" value="46.2" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="502"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="508"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Nonresponder imputation (NRI) was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Nonresponder imputation (NRI) was used for missing data.</description>
          <population>Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to tumor necrosis factor (TNF) antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.5</ci_lower_limit>
            <ci_upper_limit>32.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT_A population.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT_A population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>23.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.6</ci_lower_limit>
            <ci_upper_limit>30.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 44</time_frame>
        <population>Intent-to-treat population in Part B who were re-randomized (ITT_B_RR): All subjects who started with adalimumab at Baseline and were re-randomized at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>Intent-to-treat population in Part B who were re-randomized (ITT_B_RR): All subjects who started with adalimumab at Baseline and were re-randomized at Week 16</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>45.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.9</ci_lower_limit>
            <ci_upper_limit>61.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI75 at Week 16 (Part A)</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT_A population</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI75 at Week 16 (Part A)</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT_A population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                    <measurement group_id="O2" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>18.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.0</ci_lower_limit>
            <ci_upper_limit>24.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI100 at Week 16 (Part A)</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT_A population</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A)</title>
            <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI100 at Week 16 (Part A)</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT_A population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 44</time_frame>
        <population>ITT_B_RR population</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT_B_RR population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>32.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.8</ci_lower_limit>
            <ci_upper_limit>46.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 44</time_frame>
        <population>ITT_B_RR population</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT_B_RR population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>32.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.8</ci_lower_limit>
            <ci_upper_limit>46.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 44</time_frame>
        <population>ITT_B_RR population</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
            <description>Participants who were inadequate responders after receiving adalimumab in Part A, and rerandomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear or Almost Clear at Week 44 (Part B)</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT_B_RR population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight (≤100 kg vs &gt;100 kg) and prior exposure to TNF antagonists (0 vs ≥1).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in percentage of participants</param_type>
            <param_value>38.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.0</ci_lower_limit>
            <ci_upper_limit>55.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 48 weeks).</time_frame>
      <desc>AEs in Part A are defined as events from the first dose of study drug in Part A until prior to the first dose in Part B (Week 16) or up to 15 weeks after the last dose of study drug if the participant discontinued in Part A; AEs in Part B are defined as events from the first dose of study drug in Part B (Week 16) until up to 15 weeks after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab (Part A)</title>
          <description>Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).</description>
        </group>
        <group group_id="E2">
          <title>Risankizumab (Part A)</title>
          <description>Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).</description>
        </group>
        <group group_id="E3">
          <title>Risankizumab/Risankizumab (Part B)</title>
          <description>Participants randomized to receive double-blind (DB) risankizumab in Part A continued to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, and 28 (Part B).</description>
        </group>
        <group group_id="E4">
          <title>Adalimumab/Risankizumab (Part B)</title>
          <description>Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
        </group>
        <group group_id="E5">
          <title>Adalimumab/Rerandomized to Adalimumab (Part B)</title>
          <description>Participants who were inadequate responders after receiving adalimumab in Part A and re-randomized to continue to receive adalimumab 40 mg by subcutaneous (SC) injection every 2 weeks through Week 41 (Part B).</description>
        </group>
        <group group_id="E6">
          <title>Adalimumab/Rerandomized to Risankizumab (Part B)</title>
          <description>Participants who were inadequate responders after receiving adalimumab in Part A and re-randomized to receive risankizumab 150 mg by subcutaneous (SC) injection at Weeks 16, 20, and 32 (Part B).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Macrocornea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="301"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="301"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="294"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="304"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="301"/>
                <counts group_id="E3" events="44" subjects_affected="34" subjects_at_risk="294"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="304"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="301"/>
                <counts group_id="E3" events="48" subjects_affected="39" subjects_at_risk="294"/>
                <counts group_id="E4" events="14" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E6" events="19" subjects_affected="14" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="304"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="301"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="301"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="301"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="304"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="301"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="294"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="301"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="301"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="294"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

